Completed PHASE2 INTERVENTIONAL 2-arm NCT00228423

Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial) (CASCADE)

Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?

Sponsor: Bristol-Myers Squibb

Conditions Atherosclerosis

Interventions Clopidogrel 75 mg daily water pill daily

Updated 6 times since 2017 Last updated: Mar 30, 2021 Started: May 31, 2006 Primary completion: Jun 30, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Atherosclerosis and is currently completed. Bristol-Myers Squibb leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Ottawa Heart Institute Research Corporation
Sanofi

Data source: Ottawa Heart Institute Research Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ottawa, Canada